Novo Nordisk Heads to New Orleans With Pipeline Hopes as Headwinds Multiply
Novo Nordisk’s Wegovy loses CVS exclusivity, faces product-liability lawsuits over blindness risk, but a new Medicare program opens…
Novo Nordisk’s Contradictory Landscape: Oral Wegovy Wins a Second Market as US Headwinds Intensify
Novo Nordisk’s oral Wegovy gets UAE approval, but US pricing pressure mounts as CVS adds Lilly’s Foundayo; stock…
Novo Nordisk Faces a Pincer Movement: Legal Headwinds and a Crumbling GLP-1 Fortress
Novo Nordisk shares tumble 46% from peak after CVS strips Wegovy exclusivity, while legal cases over eye damage…
Novo Nordisk Bets on CagriSema and Oral Wegovy to Counter Pricing Headwinds and Analysts’ Caution
Novo Nordisk faces key test at ADA with CagriSema Phase 3 data; Wegovy oral prescriptions surge, European reimbursement…
Novo Nordisk Wields AI and Global Logistics to Outrun US Pricing Headwinds
Novo Nordisk tackles US pricing pressures with AI to cut clinical-to-filing time by two-thirds and a new UAE…
Novo Nordisk Juggles Pipeline Wins and Core Business Headwinds
Novo Nordisk advances rare heart disease drug Coramitug with FDA Fast Track, reports positive oral semaglutide data in…
Novo Nordisk’s Buyback and Subscription Push Amidst Revenue Headwinds
Novo Nordisk spends billions on share buybacks while forecasting a 5-13% sales decline by 2026. The firm launches…
Novo Nordisk’s Oral Ambitions Face a Formidable Rival and Fiscal Headwinds
Novo Nordisk touts superior weight loss & tolerability for its oral Wegovy pill vs Lilly’s Foundayo, while launching…
Novo Nordisk’s European Logistics Breakthrough Meets US Pricing Headwinds
EMA relaxes Wegovy cold-chain rules, cutting EU distribution costs. Novo faces 2026 sales decline from US pricing pressure…
A Defensive Move Amid Market Headwinds
Novo Nordisk launches a major share buyback despite its first revenue drop in 25 years, balancing challenges with…
Novo Nordisk Shares Face Mounting Headwinds
Novo Nordisk cuts 2026 sales outlook, faces FDA warnings and analyst downgrades as GLP-1 competition and pricing pressures…